Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
CA 2334814 A1 · Owner: Smithkline Beecham P.L.C. · Inventors: Stemp, Geoffrey; Branch, Clive Leslie; Johnson, Christopher Norbert
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds of formula (I): wherein R2 represents a hydrogen atom or a C1-4alkyl group; q is 1 or 2; A represents a group of formula (a) or (b) wherein T U, V , and Y independently represent CH or a nitrogen atom; R5 is a group selected from: a hydrogen or halogen atom, cyano C1-4alkyl or C1-4alkoxy group; s is 1 or 2. Ar2 represents an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring; and salts thereof. The compounds are useful for the treatment of conditions which require modulation of a dopamine receptor such as schizophrenia.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 1, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 1, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 1, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.